REFERENCES
- Alfthan O, Jauhiainen K, Kangas L, Käpylä H. Chemotherapy, immunotherapy, retinoids and prevention of relapses. Int J Immunotherapy 1986; 2: 5–8.
- Alfthan O, Tarkkanen J, Gröhn P, Heinonen F, Pyrhönen S, Säilä K. TigasonR (etretinate) in prevention of recurrence of superficial bladder tumors. Eur Urol 1983; 9: 6–9.
- Carbin B-E. Prognostic factors in urinary bladder cancer. Thesis. Stockholm, Kongl Carolinska Medico Chirurgiska Institutet 1990.
- DeBruyne FMJ, v.d. Meijden APM, Geboers ADH, Franssen MPH, V. Leeuwen MJW, Steerenberg PA, de Jonge WH, Ruitenberg JJ. BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer: First results of randomized trial. Urology 1988; XXXI/3: 20–25.
- DeKernion JB, Huang M-Y, Lindner A, Smith RB, Kaufman JJ. The management of superficial bladder tumors and carcinoma in situ with intravesical Bacillus Calmette-Guerin. J Urol 1985; 133: 598–601.
- Eksborg S, Nilsson SO, Edsmyr F. Intravesical instillation of AdriamvcinR. A model for standardization of the chemotherapy.” Eur Urol 1980; 6: 218–220.
- Hakulinen T, Andersen AA, Malker B, Pukkala E, Schou G, Tulinius H. Trends in cancer incidence in the nordic countries. A collaborative study of the five nordic cancer registres. Acta Pathol Scand 1986; 94: 75–77, 136–137.
- Heikkinen A. Epithelial tumours of the urinary bladder. A clinical study. Thesis. Helsinki. University of Helsinki 1984.
- Jauhiainen K. Detecting mitomycin C in human plasma during intravesical therapy. Int Urol Nephrol 1985; 17: 155–158.
- Jauhiainen K. Intravesical chemotherapy of superficial urinary bladder cancer. Thesis. Helsinki, Helsinki University Press 1986.
- Jauhiainen K, Alfthan O. Adriamycin instillations as recurrence prophylaxis in superficial urinary bladder cancer. Ann Chir Gynaec 1984; 73: 206–210.
- Jauhiainen K, Alfthan O. Methodologies for quantifying the results of intravesical chemotherapy of superficial tumors of the bladder. Med Oncol & Tumour Pharmacother 1985; 2/4: 249–254.
- Jauhiainen K, Rintala E, Alfthan O, Finnbladder Group. Immunotherapy (BCG) versus chemotherapy (MMC) in intravesical treatment of superficial urinary bladder cancer. In: Immunotherapy of urological tumours, Int. Soc. Urology Reports, ed deKernion JB, Edinburgh 1990, Churchill Livingstone, pp 13–26.
- Jauhiainen K, Sotarauta M, Permi J. Alfthan O. Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder. Eur Urol 1986; 12: 32–37.
- Kurth KH, Dalesio O, dePauw M, Ay R, Carpentier P, Mitglieder der E.O.R.T.C. GU-Gruppe. Welche oberflächlichen übergangszellkarzinome der Harnblase sollten adjuvant chemotherapeutisch behandelt werden? Akt Urol 1985; 16: 87–90.
- v.d. Meijden APM. Non specific immunotherapy with BCG-RIVM in superficial bladder cancer; Histological, immunological and therapeutic aspects. Thesis. Den Haag. 1988.
- Rintala E, Jauhiainen K, Alfthan O, the Finnbladder Research Group. Intravesical chemotherapy (MMC) vs. immunotherapy (BCG) in superficial bladder cancer. Eur Urol 1991, in press.
- Ruebben H, Graf-Dobberstein C, Ostwald R, Stauffenberg A, Jaeger N, Deutz FJ, Steffens L, Giani G. Prospective randomized study of adjuvant therapy after complete resection of superficial bladder cancer; mitomycin C vs BCG Gonnaught vs TUR alone. In: deKernion JB (ed): Immunotherapy of urological tumors. Edinburgh. Churchill Livingstone, 1990; pp. 27–36.
- Schröder FH, Sylvester R, Gustafsson H, Kawai T, Kurth KH, Matsuda M, Miyakawa M, Newling DWW, Studer E. Response criteria for phase III studies of superficial bladder cancer. In: Developments in bladder cancer, Eds. Denis L, Niijima T, Prout Jr G and Schröder FH, Alan R. Liss Inc. New York 1986; pp. 311–321.
- Silva C, Denis L, Bouffioux C, Bultinck J, V. Gangh P, Bano A, Bollack C. Epirubicin: A Phase II chemore-section study. Abstr. of 8th Congr. of EAU, London 18–21 May 1988; p. 73.
- Silverberg E. Statistical and epidemiologic data on urologic cancer. Cancer 1987; 60: 692–718.
- Soloway MS. Overview of treatment of superficial bladder cancer. Urology 1985; XXVI/4: 18–26.
- Steg A, Boiteux JP. Bladder carcinoma in situ: Conservative versus aggressive approach. In: Progress and controversies in oncological urology, (Eds) Kurth KH, Debruyne FMJ, Schroeder FH, Splinter TAW, Wagener TDJ, Alan R. Liss, New York 1984; pp. 263–274.
- Torrence RJ, Kavoussi LR, Catalona WJ, Ratliff TL. Prognostic factors in patients treated with intravesical Bacillus Calmette-Guerin for superfical bladder cancer. J Urol 1988; 139: 941–944.
- Zincke H, Utz DC, Farrow GM. Review of Mayo Clinic experience with carcinoma in situ. Urology 1985; XXVI/4: 39–46.